Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903372 | 0.90 | CYP1A2 (0.49) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL29782792 | 0.86 | CYP1A2 (0.46) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL29782769 | 0.85 | ADA (0.47) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL29782816 | 0.85 | ADA (0.47) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL6696336 | 0.81 | FGFR1 (0.43) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL6690025 | 0.81 | HPRT1 (0.46) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL29782858 | 0.79 | FDPS (0.47) | — | |
| SCHEMBL6693460 | 0.79 | AHCY (0.37) | CYP1A2 | |
| SCHEMBL6691656 | 0.78 | AHCY (0.36) | CYP1A2 | |
| SCHEMBL19662016 | 0.77 | CYP1A2 (0.50) | CYP1A2CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, POLR2H, NSUN3 | CYP1A2 1844/4885CYP2D6 2006/4885MAPK1 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.